Compare TOP & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | HROW |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | 2008 |
| Metric | TOP | HROW |
|---|---|---|
| Price | $15.62 | $30.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | 86.9K | ★ 534.4K |
| Earning Date | 07-07-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.25 | 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,723,765.00 | N/A |
| Revenue This Year | N/A | $28.59 |
| Revenue Next Year | N/A | $53.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.89 | N/A |
| 52 Week Low | $0.61 | $28.54 |
| 52 Week High | $17.42 | $54.98 |
| Indicator | TOP | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 29.69 |
| Support Level | $14.44 | $28.54 |
| Resistance Level | $16.20 | $35.43 |
| Average True Range (ATR) | 0.80 | 1.26 |
| MACD | -0.18 | -0.11 |
| Stochastic Oscillator | 64.85 | 18.71 |
TOP Financial Group Ltd is operates as an online brokerage firm in Hong Kong specializing in the trading of local and overseas equities, futures, and options products. It conduct the futures and stock brokerage business through three trading platforms, Esunny for futures trading and Longbridge for stock trading, all of which were licensed from third parties and can be easily accessed through its application, or APP, software, and websites. The three platforms are designed for seamless, efficient, and secure trading platform. The company operates and manages its business as a single operating and reportable segment.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.